Investigators at Northwestern University’s Feinberg School of Medicine have used a new mouse model of Parkinson’s disease to confirm a causal role for mitochondrial dysfunction in Parkinson’s disease. More surprisingly, the same model has called into question previously uncontroversial notions about the motor features that are PD’s most conspicuous feature.
Supernus Pharmaceuticals Inc. CEO Jack Khattar, in disclosing his firm’s plan to acquire Adamas Pharmaceuticals Inc., said the team there has made “significant progress in redirecting” the Parkinson’s disease (PD) drug Gocovri (amantadine), but plenty more potential remains on the table with the oral selective RET kinase inhibitor.
Rune Labs Inc. is on a mission to make the mysteries of the brain easier to read for both clinicians and biopharma companies. Having a fresh $22.8 million in a series A financing on the books will no doubt make the goal easier to reach.
Rune Labs Inc. is on a mission to make the mysteries of the brain easier to read for both clinicians and biopharma companies. Having a fresh $22.8 million in a series A financing on the books will no doubt make the goal easier to reach. The new round pushed total funding for development of the San Francisco-based company’s brain data software platform to $30.1 million.
Chicago-based Vanqua Bio Inc. has raised $85 million in series B financing to accelerate development of its therapies tackling Parkinson’s and other neurodegenerative diseases. Founded in 2019, Vanqua’s technology is focused on developing small-molecule activators of glucocerebrosidase, an enzyme that regulates levels of lipids in cells.
Cala Health Inc. is moving quickly to establish leadership in treatment for essential tremor with its recent inclusion in the International Essential Tremor Foundation (IETF) guidelines as the only non-pharmacological, non-surgical treatment recommended and positive treatment results from a real-world study. “We’re very pleased with the validation from IETF and the research presented at MDS that demonstrates the impactful benefit of our therapy for those suffering from essential tremor,” said Kate Rosenbluth, founder and chief science officer of Cala Health.
LONDON – A significant body of research indicates inhibition of the mitochondrial permeability transition pore (PTP) would reduce neuroinflammation and protect neurons, but the difficulty of finding inhibitors that cross the blood-brain barrier to regulate the pore has left the therapeutic potential largely untapped.
Following new positive top-line results from its pivotal phase III study of IPX-203, Amneal Pharmaceuticals Inc. said an NDA submission for the Parkinson’s disease therapy (PD) is now planned for the middle of 2022.
In one of the biggest collaboration deals of the year, Shape Therapeutics Inc. entered a collaboration and license agreement with Roche Holding AG to develop gene therapies for targets in areas that include Alzheimer’s disease, Parkinson’s disease and rare diseases. Seattle-based Shape is eligible to receive an initial payment, development, regulatory and sales milestone payments that could exceed $3 billion in aggregate value.
Annovis Bio Inc. presented new clinical efficacy and biomarker data from two phase II studies of its lead candidate, ANVS-401 (posiphen), at the 2021 Alzheimer's Association International Conference (AAIC) that saw the stock sink soon afterward. The Berwyn, Pa.-based company’s shares (NYSE:ANVS) took a powerful hit as shares had plunged a dramatic 60% to close at $43.50 each on July 29.
